The University places importance on supporting academics and researchers through the process of commercialising their research. This is evident through the University’s Enterprise Investment Fund (EIF) scheme. Funding is available for staff to de-risk technologies developed at the University, for commercialisation with industry, typically leading to a licence deal or spin-out.
A list of technologies currently available for licensing can be found below:
- A multiplexible single colour probe for monitoring GTPase activation
- A new chemical cross linker for the treatment of keratoconus
- A new contact lens to prevent and treat infections of the cornea
- Novel cost-effective protein-based vaccine against pneumococcal invasive disease
- A novel protein nanocage for enzyme encapsulation and molecule delivery
- CageCapture: removing toxic pollutants from the air using nanocage technology
- Decoupling electronic and thermal transport in N-type oxide thermoelectrics
- Flexible PCB-based drift tube for ion mobility and hyphenated spectrometry
- Galectin-3: a therapeutic target for cancer and tissue fibrosis
- Hyperbrached polydendrons – a unique dendrimer analogue platform technology
- Injectable stem cell therapy for osteoarthritis
- Livar autonomous robot chemists
- Neutrophil extracellular traps formation assay for ICU precision medicine
- New method for the conversion of methane and carbon dioxide
- New predictive biomarker for adrenal suppression
- New selective anti-complement molecules
- New vaccine for canine heartworm
- Next generation optical coherence tomography device
- Novel bioengineered substrates for pluripotent stem cell culture
- Novel design of cryogenic pump
- Novel sulphur polymers for heavy metal capture
- Optimised screening for pancreatic cancer
- Porous liquids for selective uptake and release of gases
- PPH butterfly: a novel device to treat postpartum haemorrhage
- Propofol derivatives for the management of chronic pain
- Sharp novel super hydrophobic polymers
- The design and testing of a novel fasciola vaccine
- Therapeutic tamponades
- Use of in-vitro aged undifferentiated mesenchymal stem cells to drive healing
- Toxin detection test
- Trail fusion protein novel gene therapy for oncology
- Treatment of bleeding disorders with novel pro-coagulant compounds
Back to: Research